Skip to main content
Premium Trial:

Request an Annual Quote

CeMines Estonian Subsidiary Receives CE Mark for Lung Cancer Dx

NEW YORK, Jan. 12 (GenomeWeb News) - The European Union's regulatory body cleared the CellCorrect Lab Detection Kit for clinical use, CeMines said today.

 

EU's State Agency of Medicines-Department of Medical Devices on Dec. 30, 2005, granted the CE Mark for the molecular blood test to detect and diagnose lung cancer. CeMines Estonia OU, a wholly owned subsidiary, filed for CE Mark registration in September 2005.  

 

CeMines Estonia will market and distribute the test under the brand name CellCorrect KvA-40 LAb Kit.

 

CeMines filed a 501(k) application for CellCorrect Lab with the US Food and Drug Administration in May 2005. Claiming "productive discussions" with the FDA, the company expects "substantial forward progress" in 2006.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.